Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1440 - 1440

Published: Feb. 8, 2025

Antibody-based immune-stimulating drugs (ABIs) represent a transformative frontier in cancer immunotherapy, designed to reshape the tumor microenvironment and overcome immune suppression. This study highlighted recent advances ABIs, including antibody conjugates (ISACs), bispecific antibodies (BsAbs), checkpoint blockade enhancers, with focus on their mechanisms of action, clinical advancements, challenges. Preclinical findings revealed that ISACs effectively boost overall anti-cancer immunity by reprogramming tumor-associated macrophages, enhancing T cell activation, engaging other pathways. Similarly, BsAbs redirect cells tumors, achieving significant regression. Additionally, artificial intelligence (AI) is revolutionizing development ABIs optimizing drug design, identifying novel targets, accelerating preclinical validation, enabling personalized therapeutic strategies. Despite these challenges remain, resistance off-target effects. Future research should prioritize next-generation multifunctional antibodies, AI-driven innovations, combination therapies enhance efficacy expand applications. Connecting gaps could unlock full potential upgrading treatment improving outcomes for patients refractory or resistant tumors.

Language: Английский

Enzyme-catalyzed synthesis of mannose ester and its enhancement of tanshinone and glycyrrhetinic acid lipid nanoparticles

Journal of Traditional Chinese Medical Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский